Isao Matsumoto

Professor

University of Tsukuba
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (18)

Objectives Rituximab (RTX) is a key treatment for ANCA-associated vasculitis (AAV), but RTX-induced acute thrombocytopenia (RIAT) remains a concern. We aimed to evaluate the risk and risk factors of RIAT in patients with AAV undergoing RTX induction therapy. Methods Patients with new-onset microscopic polyangiitis or granulomatosis with polyangiitis who received RTX in a nationwide multicentre registry in Japan were included. RIAT was defined by platelet count reductions within 28 days post-RTX. Risk factors for RIAT were identified by using logistic regression with stepwise selection, and prediction models were developed. Model performance was assessed using C-statistics. Results Among 175 patients with AAV receiving RTX, RIAT occurred in 35.4% of them. Diabetes mellitus (odds ratio [OR] = 4.96), cardiac disease (OR = 3.57), low platelet count (OR = 1.04 per 104/μl decrease), increased serum creatinine (OR = 1.44 per 1 mg/dl increase), low albumin (OR = 2.33 per 1 g/dl decrease), and high KL-6 (OR = 1.09 per 100 U/ml increase) were identified as significant predictors. A predictive model incorporating these factors achieved a C-statistic of 0.817. Conclusion RIAT is a frequent complication of RTX induction in patients with AAV, with diabetes mellitus and cardiac disease being strong risk factors. Our predictive model enables risk assessment for RIAT, allowing clinicians to optimize treatment strategies.

Year:

2026

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ involvement. It is known that cytokines produced from activated CD4+ T cells play a pivotal role in the development of SLE; however, the details of pathological processes remain unclear. The purpose of this study is to elucidate the role of activated CD4+ T cells on the pathogenesis of lupus using SLE murine models induced by toll like receptor 7 agonist imiquimod (IMQ). Lupus was induced in wild-type (WT) and interferon γ (IFNγ)-deficient (IFNγ−/−) mice by topical IMQ treatment. Splenic T and B cell subsets were analyzed by flow cytometry. CD4+ T cells and B cells were isolated for co-culture to assess B cell differentiation and IgG production. Comprehensive lupus-like phenotypes were evaluated. Single-cell RNA sequencing (scRNA-seq) was performed to characterize IFNγ-associated cellular and molecular pathways. IMQ treatment increased IFNγ-producing CD4+ T cells, along with Tfh cells, Tph cells, age-associated B cells, and plasma cells in WT mice. CD4+ T cells from IMQ-treated WT mice promoted B-cell differentiation and IgG production in co-culture assays. In IFNγ−/− mice, lupus-like phenotypes were significantly attenuated, and co-cultured B cells showed reduced differentiation and IgG production. Single-cell RNA sequencing revealed that IFNγ plays a critical role in promoting B cell differentiation and autoantibody production. IFNγ derived from activated CD4+ T cells plays a critical role in driving B-cell differentiation and promoting autoantibody production in IMQ-induced lupus.

Year:

2026

Objectives To evaluate the real-world effectiveness of rituximab (RTX) and intravenous cyclophosphamide (IVCY) compared to non-use for remission induction in microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Methods This observational study emulated a target trial using data from the Japan Collaborative Registry of ANCA-associated Vasculitis. Patients aged ≥20 years with newly diagnosed or relapsing MPA or GPA (2017–23) were included. RTX or IVCY use within 4 weeks defined the treatment group; others formed the control group. The primary outcome was failure to achieve remission at week 24 (Birmingham Vasculitis Activity Score = 0 and prednisolone ≤ 10 mg/day). Secondary outcomes included a composite of death, kidney failure, and relapse, and serious infection. In inverse probability weighted population, risk ratios were estimated using modified Poisson regression. Results Among 544 patients (MPA: 413, GPA: 131), 63.6% received RTX or IVCY. The risk ratio for failure to achieve remission was 0.72 (95% CI: 0.61–0.85), and for the composite outcome was 0.57 (95% CI: 0.33–0.97), and for serious infection was 1.03 (95% CI: 0.47–2.25). Results were robust in sensitivity analyses. Conclusions RTX and IVCY improved short-term outcomes in MPA and GPA without increasing infection risk, supporting their recommendation as standard therapy.

Year:

2026

Objective To clarify T/B cell-specific gene expression patterns using RNA-Seq in IgG4-related disease (IgG4-RD). Methods Pathologically confirmed submandibular gland (SMG) (n = 3) and peripheral blood mononuclear cells (PBMC) (n = 4) from four treatment-naïve patients with definite IgG4-RD, as well as PBMCs from primary Sjögren syndrome (pSS) (n = 3) and healthy controls (HCs) (n = 3), were collected, and subsequently Pan T and CD19+ B cells were sorted. We conducted RNA sequencing to compare the gene expressions of Pan T and CD19+ B cells in SMGs and PBMCs in IgG4-RD or IgG4-RD versus pSS and HCs in PBMCs. Ingenuity pathway analysis (IPA) and qPCR validation were performed for differentially expressed genes (DEGs). Results Principal component analysis (PCA) results showed the gene expression patterns of Pan T and CD19+ B cells derived from SMGs differed from those derived from PBMCs in IgG4-RD. However, the gene expression patterns of Pan T and CD19+ B cells derived from PBMCs were not clustered between groups. A total of 214 upregulated and 50 downregulated DEGs in Pan T cells and 630 upregulated and 109 downregulated DEGs in CD19+ B cells were identified in SMGs compared with PBMCs in IgG4-RD. The upregulated DEGs in SMGs of IgG4-RD included cytokines, chemokines, and transcription regulators. IPA for these DEGs clarified immune system-related pathways were positively regulated in SMGs compared with PBMCs in IgG4-RD. Quantitative PCR validated significantly increased mRNA expression of IL-21 and EGR2 by Pan T cells in SMGs compared with PBMCs of IgG4-RD. Conclusion RNA-Seq clarified the DEGs of Pan T and CD19+ B cells from SMGs in comparison with PBMCs, which might contribute to the pathogenesis of IgG4-RD.

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Objective To compare clinicopathological phenotype-based, anti-neutrophil cytoplasmic antibody (ANCA) serotype-based, and unsupervised data-driven classifications in relation to clinical outcomes and patient heterogeneity in a large Japanese cohort with ANCA-associated vasculitis (AAV). Methods This multicentre, retrospective cohort study analysed data from a nationwide Japanese registry of 729 newly diagnosed patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), all positive for myeloperoxidase (MPO)- or proteinase 3 (PR3)-ANCA. Patients were classified by phenotype, serotype, combined phenotype-serotype groupings, and data-driven clustering based on baseline clinical and laboratory features. Associations with clinical outcomes—including mortality, relapse, and response to rituximab (RTX) versus cyclophosphamide (IVCY)—were evaluated using inverse probability of treatment weighting (IPW). Results Phenotype-based classification more accurately distinguished all-cause mortality risk (MPA vs. GPA: hazard ratio [HR] 2.53, 95% CI 1.34–4.76). Combined phenotype-serotype analysis identified MPO-MPA patients with the highest mortality (HR 3.45, 95% CI 1.09-11.0, vs. PR3-GPA) and PR3-GPA with the highest severe relapse. Discordant groups, such as MPO-GPA, demonstrated unique clinical characteristics. After IPW adjustment, no significant difference in 24-week remission rates was observed between RTX and IVCY across classifications, both overall (RR 1.02, 95% CI 0.95–1.09) and within subgroups. Unsupervised clustering identified four distinct clinical subgroups, with limited concordance with conventional phenotype or serotype classifications. Conclusion Phenotype and serotype classifications provide complementary, not competing, prognostic insights in Japanese patients with AAV. Data-driven clustering revealed additional clinical heterogeneity not captured by traditional systems, underscoring the need for integrated, multi-dimensional stratification approaches to improve personalised risk assessment and treatment strategies.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (17)

Wells Messersmith

Professor and Cancer Center Director

University of Colorado Cancer Center

UNITED STATES
View details

Alessandro Zerbi

Director

Humanitas University

ITALY
View details

Ammar Javed

Assistant Professor

NYU Langone Health

UNITED STATES
View details

Yoshia Miyawaki

Special-Appointment Assistant Professor

Okayama Daigaku

JAPAN
View details

Kazushi Maruo

Associate professor

University of Tsukuba

JAPAN
View details

Maria João Amaral

University of Coimbra

PORTUGAL
View details

Gennaro Nappo

Humanitas University

ITALY
View details

Knut Jørgen Labori

Professor

Oslo University Hospital

NORWAY
View details

Nigel Jamieson

University of Glasgow

UNITED KINGDOM
View details

Toshiko Ito-Ihara

Specially Appointed Professor

Kyoto Prefectural University of Medicine

JAPAN
View details

Jozef Urdzik

Uppsala University

SWEDEN
View details

Hiromitsu Asashima

University of Tsukuba

JAPAN
View details

Masaru Shimizu

Specially Appointed Lecturer

University of Tsukuba

JAPAN
View details

Tsukasa Saida

Associate Professor

University of Tsukuba

JAPAN
View details

Elizabeth Pando

Universitat Autònoma de Barcelona (UAB)

SPAIN
View details

Yuya Kondo

Lecturer

University of Tsukuba

JAPAN
View details

Daisuke Hashimoto

Kansai Medical University

JAPAN
View details